{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:02:24Z","timestamp":1793782944941,"version":"4.6.1"},"reference-count":108,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40620-016-0357-7","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T05:16:10Z","timestamp":1479186970000},"page":"347-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab"],"prefix":"10.1093","volume":"30","author":[{"given":"Arif","family":"Asif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"key":"357_CR1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654\u2013666","journal-title":"N Engl J Med"},{"key":"357_CR2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","volume":"347","author":"JL Moake","year":"2002","unstructured":"Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589\u2013600","journal-title":"N Engl J Med"},{"key":"357_CR3","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676\u20131687","journal-title":"N Engl J Med"},{"key":"357_CR4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A et al (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554\u2013562","journal-title":"Clin J Am Soc Nephrol"},{"key":"357_CR5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nefro.2015.07.005","volume":"35","author":"JM Campistol","year":"2015","unstructured":"Campistol JM, Arias M, Ariceta G et al (2015) An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 35:421\u2013447","journal-title":"Nefrologia"},{"key":"357_CR6","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1097\/MJT.0b013e31829b59dc","volume":"23","author":"A Nayer","year":"2016","unstructured":"Nayer A, Asif A (2016) Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther 23:e151\u2013e158","journal-title":"Am J Ther"},{"key":"357_CR7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/adc.76.6.518","volume":"76","author":"TJ Neuhaus","year":"1997","unstructured":"Neuhaus TJ, Calonder S, Leumann EP (1997) Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child 76:518\u2013521","journal-title":"Arch Dis Child"},{"key":"357_CR8","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"AL Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA et al (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392\u20132400","journal-title":"J Am Soc Nephrol"},{"key":"357_CR9","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844\u20131859","journal-title":"Clin J Am Soc Nephrol"},{"key":"357_CR10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","volume":"27","author":"LM Geerdink","year":"2012","unstructured":"Geerdink LM, Westra D, van Wijk JA et al (2012) Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 27:1283\u20131291","journal-title":"Pediatr Nephrol"},{"key":"357_CR11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","volume":"24","author":"G Ariceta","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S et al (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687\u2013696","journal-title":"Pediatr Nephrol"},{"key":"357_CR12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1262890","volume":"36","author":"C Loirat","year":"2010","unstructured":"Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T (2010) Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 36:673\u2013681","journal-title":"Semin Thromb Hemost"},{"key":"357_CR13","volume-title":"Soliris (eculizumab) [prescribing information]","author":"US Food and Drug Administration","year":"2015","unstructured":"US Food and Drug Administration (2015) Soliris (eculizumab) [prescribing information]. Alexion Pharmaceuticals, Inc., Cheshire, CT"},{"key":"357_CR14","volume-title":"Soliris (eculizumab) [summary of product characteristics]","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency (2015) Soliris (eculizumab) [summary of product characteristics]. Alexion Europe SAS, Paris"},{"key":"357_CR15","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"357_CR16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P et al (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061\u20131073","journal-title":"Kidney Int"},{"key":"357_CR17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G et al (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711","journal-title":"Kidney Int"},{"key":"357_CR18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM et al (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84\u201393","journal-title":"Am J Kidney Dis"},{"key":"357_CR19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","volume":"40","author":"M Riedl","year":"2014","unstructured":"Riedl M, Fakhouri F, Le Quintrec M et al (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40:444\u2013464","journal-title":"Semin Thromb Hemost"},{"key":"357_CR20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldl004","volume":"77 and 78","author":"D Kavanagh","year":"2006","unstructured":"Kavanagh D, Goodship THJ, Richards A (2006) Atypical haemolytic uraemic syndrome. Br Med Bull 77 and 78:5\u201322","journal-title":"Br Med Bull"},{"key":"357_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10641963.2010.503303","volume":"33","author":"T Akimoto","year":"2011","unstructured":"Akimoto T, Muto S, Ito C et al (2011) Clinical features of malignant hypertension with thrombotic microangiopathy. Clin Exp Hypertens 33:77\u201383","journal-title":"Clin Exp Hypertens"},{"key":"357_CR22","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/ndt\/gfs279","volume":"27","author":"T Barbour","year":"2012","unstructured":"Barbour T, Johnson S, Cohney S, Hughes P (2012) Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 27:2673\u20132685","journal-title":"Nephrol Dial Transplant"},{"key":"357_CR23","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/asheducation.V2012.1.617.3798924","volume":"2012","author":"CM Nester","year":"2012","unstructured":"Nester CM, Thomas CP (2012) Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program 2012:617\u2013625","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"357_CR24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","volume":"8","author":"M Noris","year":"2012","unstructured":"Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8:622\u2013633","journal-title":"Nat Rev Nephrol"},{"key":"357_CR25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A (2013) Atypical hemolytic uremic syndrome. Semin Nephrol 33:508\u2013530","journal-title":"Semin Nephrol"},{"key":"357_CR26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/2040620715571076","volume":"6","author":"N Khanal","year":"2015","unstructured":"Khanal N, Dahal S, Upadhyay S, Bhatt VR, Bierman PJ (2015) Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. Ther Adv Hematol 6:97\u2013102","journal-title":"Ther Adv Hematol"},{"key":"357_CR27","first-page":"662","volume":"91","author":"JS Dashe","year":"1998","unstructured":"Dashe JS, Ramin SM, Cunningham FG (1998) The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol 91:662\u2013668","journal-title":"Obstet Gynecol"},{"key":"357_CR28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","volume":"21e","author":"F Fakhouri","year":"2010","unstructured":"Fakhouri F, Roumenina L, Provot F et al (2010) Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21e:859\u2013867","journal-title":"J Am Soc Nephrol"},{"key":"357_CR29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","volume":"44","author":"AJ Vaught","year":"2016","unstructured":"Vaught AJ, Gavriilaki E, Hueppchen N et al (2016) Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. Exp Hematol 44:390\u2013398","journal-title":"Exp Hematol"},{"key":"357_CR30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.transci.2011.04.004","volume":"44","author":"M Shrivastava","year":"2011","unstructured":"Shrivastava M, Modi G, Singh RK, Navaid S (2011) Early diagnosis and management of postpartum hemolytic uremic syndrome with plasma exchange. Transfus Apher Sci 44:257\u2013262","journal-title":"Transfus Apher Sci"},{"key":"357_CR31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13000-015-0278-0","volume":"10","author":"J Mu","year":"2015","unstructured":"Mu J, Zhang J, Sunnassee A, Dong H (2015) A case report of undiagnosed postpartum hemolytic uremic syndrome. Diagn Pathol 10:89","journal-title":"Diagn Pathol"},{"key":"357_CR32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1471-0528.1972.tb15791.x","volume":"79","author":"GD Calvert","year":"1972","unstructured":"Calvert GD (1972) Postpartum haemolytic uraemic syndrome: case report and brief review. J Obstet Gynaecol Br Commonw 79:244\u2013249","journal-title":"J Obstet Gynaecol Br Commonw"},{"key":"357_CR33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ckj\/sfs185","volume":"6","author":"Y Delmas","year":"2013","unstructured":"Delmas Y, Bordes C, Loirat C, Fremeaux-Bacchi V, Combe C (2013) Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin Kidney J 6:243\u2013244","journal-title":"Clin Kidney J"},{"key":"357_CR34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AOG.0b013e31828e2612","volume":"122","author":"G Ardissino","year":"2013","unstructured":"Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M (2013) Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 122:487\u2013489","journal-title":"Obstet Gynecol"},{"key":"357_CR35","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","volume":"92","author":"R Carr","year":"2013","unstructured":"Carr R, Cataland SR (2013) Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. Ann Hematol 92:845\u2013846","journal-title":"Ann Hematol"},{"key":"357_CR36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/0003-4819-159-1-201307020-00023","volume":"159","author":"S Zschiedrich","year":"2013","unstructured":"Zschiedrich S, Prager EP, Kuehn EW (2013) Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab. Ann Intern Med 159:76","journal-title":"Ann Intern Med"},{"key":"357_CR37","first-page":"1421","volume":"93","author":"C Canigral","year":"2014","unstructured":"Canigral C, Moscardo F, Castro C et al (2014) Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann Hematol 93:1421\u20131422","journal-title":"Ann Hematol"},{"key":"357_CR38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.transci.2014.08.027","volume":"51","author":"MP Mussoni","year":"2014","unstructured":"Mussoni MP, Veneziano FA, Boetti L, et al. (2014) Innovative therapeutic approach: sequential treatment with plasma exchange and eculizumab in a pregnant woman affected by atypical hemolytic-uremic syndrome. Transfus Apher Sci 51:134\u2013136","journal-title":"Transfus Apher Sci"},{"key":"357_CR39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40620-015-0173-5","volume":"28","author":"Amorim E Sousa De","year":"2015","unstructured":"De Sousa Amorim E, Blasco M, Quintana L, Sole M, de Cordoba SR, Campistol JM (2015) Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J Nephrol 28:641\u2013645","journal-title":"J Nephrol"},{"key":"357_CR40","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1055\/s-0036-1579539","volume":"6","author":"AF Saad","year":"2016","unstructured":"Saad AF, Roman J, Wyble A, Pacheco LD (2016) Pregnancy-associated atypical hemolytic-uremic syndrome. AJP Rep 6:e125\u2013128","journal-title":"AJP Rep"},{"key":"357_CR41","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/AOG.0000000000001340","volume":"127","author":"HM Tsai","year":"2016","unstructured":"Tsai HM, Kuo E (2016) From gestational hypertension and preeclampsia to atypical hemolytic uremic syndrome. Obstet Gynecol 127:907\u2013910","journal-title":"Obstet Gynecol"},{"key":"357_CR42","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","volume":"373","author":"RJ Kelly","year":"2015","unstructured":"Kelly RJ, Hochsmann B, Szer J et al (2015) Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 373:1032\u20131039","journal-title":"N Engl J Med"},{"key":"357_CR43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","volume":"220","author":"RF Hallstensen","year":"2015","unstructured":"Hallstensen RF, Bergseth G, Foss S et al (2015) Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 220:452\u2013459","journal-title":"Immunobiology"},{"key":"357_CR44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12185-016-1946-x","volume":"103","author":"N Miyasaka","year":"2016","unstructured":"Miyasaka N, Miura O, Kawaguchi T et al (2016) Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol 103:703\u2013712","journal-title":"Int J Hematol"},{"key":"357_CR45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1291\/hypres.28.89","volume":"28","author":"Y Shibagaki","year":"2005","unstructured":"Shibagaki Y, Fujita T (2005) Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)\/thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Hypertens Res 28:89\u201395","journal-title":"Hypertens Res"},{"key":"357_CR46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","volume":"45","author":"BJ Born van den","year":"2005","unstructured":"van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA (2005) Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 45:246\u2013251","journal-title":"Hypertension"},{"key":"357_CR47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jash.2015.12.007","volume":"10","author":"RO Mathew","year":"2016","unstructured":"Mathew RO, Nayer A, Asif A (2016) The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J Am Soc Hypertens 10:352\u2013359","journal-title":"J Am Soc Hypertens"},{"key":"357_CR48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.1982.tb01345.x","volume":"13","author":"P Kincaid-Smith","year":"1982","unstructured":"Kincaid-Smith P (1982) Renal pathology in hypertension and the effects of treatment. Br J Clin Pharmacol 13:107\u2013115","journal-title":"Br J Clin Pharmacol"},{"key":"357_CR49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","volume":"103","author":"CA Farquharson","year":"2002","unstructured":"Farquharson CA, Struthers AD (2002) Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 103:425\u2013431","journal-title":"Clin Sci (Lond)"},{"key":"357_CR50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jsbmb.2008.03.005","volume":"109","author":"V Cachofeiro","year":"2008","unstructured":"Cachofeiro V, Miana M, de Las Heras N et al (2008) Aldosterone and the vascular system. J Steroid Biochem Mol Biol 109:331\u2013335","journal-title":"J Steroid Biochem Mol Biol"},{"key":"357_CR51","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0b013e328345023d","volume":"29","author":"BJH Born van den","year":"2011","unstructured":"van den Born BJH, Lowenberg EC, van der Hoeven NV et al (2011) Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens 29:922\u2013927","journal-title":"J Hypertens"},{"key":"357_CR52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jch.12664","volume":"18","author":"HM Tsai","year":"2016","unstructured":"Tsai HM (2016) Does anticomplement therapy have a role in the management of malignant hypertension? J Clin Hypertens (Greenwich) 18:359\u2013360","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"357_CR53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0009922811412942","volume":"52","author":"A Totina","year":"2013","unstructured":"Totina A, Iorember F, El-Dahr SS, Yosypiv IV (2013) Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension. Clin Pediatr (Phila) 52:183\u2013186","journal-title":"Clin Pediatr (Phila)"},{"key":"357_CR54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.12659\/AJCR.895098","volume":"16","author":"A Rafiq","year":"2015","unstructured":"Rafiq A, Tariq H, Abbas N, Shenoy R (2015) Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep 16:109\u2013114","journal-title":"Am J Case Rep"},{"key":"357_CR55","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1291\/hypres.31.479","volume":"31","author":"B Zhang","year":"2008","unstructured":"Zhang B, Xing C, Yu X, Sun B, Zhao X, Qian J (2008) Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res 31:479\u2013483","journal-title":"Hypertens Res"},{"key":"357_CR56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00467-010-1708-6","volume":"26","author":"SI Al-Akash","year":"2011","unstructured":"Al-Akash SI, Almond PS, Savell VH Jr, Gharaybeh SI, Hogue C (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 26:613\u2013619","journal-title":"Pediatr Nephrol"},{"key":"357_CR57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ndtplus\/sfr157","volume":"5","author":"M Garjau","year":"2012","unstructured":"Garjau M, Azancot M, Ramos R, Sanchez-Corral P, Montero MA, Seron D (2012) Early treatment with eculizumab in atypical haemolytic uraemic syndrome. Clin Kidney J 5:31\u201333","journal-title":"Clin Kidney J"},{"key":"357_CR58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00467-012-2296-4","volume":"28","author":"N Besbas","year":"2013","unstructured":"Besbas N, Gulhan B, Karpman D et al (2013) Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 28:155\u2013158","journal-title":"Pediatr Nephrol"},{"key":"357_CR59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ccr3.59","volume":"2","author":"T Sajan","year":"2014","unstructured":"Sajan T, Vinay S, Sonu N, Alan P (2014) How atypical can atypical hemolytic uremic syndrome be? Clin Case Rep 2:57\u201359","journal-title":"Clin Case Rep"},{"key":"357_CR60","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00467-014-2975-4","volume":"30","author":"T Ohta","year":"2015","unstructured":"Ohta T, Urayama K, Tada Y et al (2015) Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol 30:603\u2013608","journal-title":"Pediatr Nephrol"},{"key":"357_CR61","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13256-015-0575-y","volume":"9","author":"M Sevinc","year":"2015","unstructured":"Sevinc M, Basturk T, Sahutoglu T et al (2015) Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report. J Med Case Rep 9:92","journal-title":"J Med Case Rep"},{"key":"357_CR62","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5414\/CN108532","volume":"84","author":"S Sharma","year":"2015","unstructured":"Sharma S, Pradhan M, Meyers KE, Le Palma K, Laskin BL (2015) Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab. Clin Nephrol 84:181\u2013185","journal-title":"Clin Nephrol"},{"key":"357_CR63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643\u2013657","journal-title":"Nat Rev Nephrol"},{"key":"357_CR64","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Le Quintrec","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B et al (2013) Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13:663\u2013675","journal-title":"Am J Transplant"},{"key":"357_CR65","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber J, Le Quintrec M, Krid S et al (2012) Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 12:3337\u20133354","journal-title":"Am J Transplant"},{"key":"357_CR66","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/BOR.0b013e328356896b","volume":"24","author":"BW Ornstein","year":"2012","unstructured":"Ornstein BW, Atkinson JP, Densen P (2012) The complement system in pediatric systemic lupus erythematosus, atypical hemolytic uremic syndrome, and complocentric membranoglomerulopathies. Curr Opin Rheumatol 24:522\u2013529","journal-title":"Curr Opin Rheumatol"},{"key":"357_CR67","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1136\/annrheumdis-2014-205287","volume":"73","author":"J Leffler","year":"2014","unstructured":"Leffler J, Bengtsson AA, Blom AM (2014) The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 73:1601\u20131606","journal-title":"Ann Rheum Dis"},{"key":"357_CR68","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.semnephrol.2015.08.006","volume":"35","author":"DJ Birmingham","year":"2015","unstructured":"Birmingham DJ, Hebert LA (2015) The complement system in lupus nephritis. Semin Nephrol 35:444\u2013454","journal-title":"Semin Nephrol"},{"key":"357_CR69","doi-asserted-by":"crossref","first-page":"e1002079","DOI":"10.1371\/journal.pgen.1002079","volume":"7","author":"J Zhao","year":"2011","unstructured":"Zhao J, Wu H, Khosravi M et al (2011) Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 7:e1002079","journal-title":"PLoS Genet"},{"key":"357_CR70","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/ar3539","volume":"13","author":"A Jonsen","year":"2011","unstructured":"Jonsen A, Nilsson SC, Ahlqvist E et al (2011) Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 13:R206","journal-title":"Arthritis Res Ther"},{"key":"357_CR71","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/rheumatology\/keq311","volume":"50","author":"MH Chen","year":"2011","unstructured":"Chen MH, Chen MH, Chen WS et al (2011) Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology (Oxford) 50:768\u2013775","journal-title":"Rheumatology (Oxford)"},{"key":"357_CR72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/oxfordjournals.ndt.a027822","volume":"13","author":"F Bridoux","year":"1998","unstructured":"Bridoux F, Vrtovsnik F, Noel C et al (1998) Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dial Transplant 13:298\u2013304","journal-title":"Nephrol Dial Transplant"},{"key":"357_CR73","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","volume":"15","author":"D Song","year":"2013","unstructured":"Song D, Wu LH, Wang FM et al (2013) The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 15:R12","journal-title":"Arthritis Res Ther"},{"key":"357_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-0172(98)80023-1","volume":"28","author":"F Musio","year":"1998","unstructured":"Musio F, Bohen EM, Yuan CM, Welch PG (1998) Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 28:1\u201319","journal-title":"Semin Arthritis Rheum"},{"key":"357_CR75","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0272-6386(12)80885-7","volume":"18","author":"G Banfi","year":"1991","unstructured":"Banfi G, Bertani T, Boeri V et al (1991) Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 18:240\u2013248","journal-title":"Am J Kidney Dis"},{"key":"357_CR76","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0049-0172(94)90073-6","volume":"24","author":"R Jain","year":"1994","unstructured":"Jain R, Chartash E, Susin M, Furie R (1994) Systemic lupus erythematosus complicated by thrombotic microangiopathy. Semin Arthritis Rheum 24:173\u2013182","journal-title":"Semin Arthritis Rheum"},{"key":"357_CR77","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/ard.2005.041673","volume":"65","author":"S Giannouli","year":"2006","unstructured":"Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG (2006) Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 65:144\u2013148","journal-title":"Ann Rheum Dis"},{"key":"357_CR78","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1445-5994.2011.02591.x","volume":"42","author":"M Samson","year":"2012","unstructured":"Samson M, Audia S, Leguy V et al (2012) Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange. Intern Med J 42:95\u201398","journal-title":"Intern Med J"},{"key":"357_CR79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","volume":"30","author":"R Coppo","year":"2015","unstructured":"Coppo R, Peruzzi L, Amore A et al (2015) Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 30:167\u2013172","journal-title":"Pediatr Nephrol"},{"key":"357_CR80","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","volume":"65","author":"A El-Husseini","year":"2015","unstructured":"El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP (2015) Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 65:127\u2013130","journal-title":"Am J Kidney Dis"},{"key":"357_CR81","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1445-5994.2012.02810.x","volume":"42","author":"R Ramachandran","year":"2012","unstructured":"Ramachandran R, Sakhuja V, Jha V, Kohli HS, Rathi M (2012) Plasmapheresis in systemic lupus erythematosus with thrombotic microangiopathy. Intern Med J 42:734","journal-title":"Intern Med J"},{"key":"357_CR82","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10157-010-0300-5","volume":"14","author":"C Gharbi","year":"2010","unstructured":"Gharbi C, Bourry E, Rouvier P et al (2010) Rapidly progressive lupus nephritis and concomitant thrombotic microangiopathy. Clin Exp Nephrol 14:487\u2013491","journal-title":"Clin Exp Nephrol"},{"key":"357_CR83","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","volume":"11","author":"K Hadaya","year":"2011","unstructured":"Hadaya K, Ferrari-Lacraz S, Fumeaux D et al (2011) Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11:2523\u20132527","journal-title":"Am J Transplant"},{"key":"357_CR84","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/08860229609047679","volume":"18","author":"P Stratta","year":"1996","unstructured":"Stratta P, Besso L, Ferrero S et al (1996) Scleroderma renal crisis is still a life-threatening syndrome. Ren Fail 18:567\u2013574","journal-title":"Ren Fail"},{"key":"357_CR85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0272-6386(12)70166-X","volume":"22","author":"U Zwettler","year":"1993","unstructured":"Zwettler U, Andrassy K, Waldherr R, Ritz E (1993) Scleroderma renal crisis as a presenting feature in the absence of skin involvement. Am J Kidney Dis 22:53\u201356","journal-title":"Am J Kidney Dis"},{"key":"357_CR86","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1346-8138.1997.tb02769.x","volume":"24","author":"K Yamanaka","year":"1997","unstructured":"Yamanaka K, Mizutani H, Hashimoto K, Nishii M, Shimizu M (1997) Scleroderma renal crisis complicated by hemolytic uremic syndrome in a case of elderly onset systemic sclerosis. J Dermatol 24:184\u2013188","journal-title":"J Dermatol"},{"key":"357_CR87","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0272-6386(89)80155-6","volume":"14","author":"DM Ricker","year":"1989","unstructured":"Ricker DM, Sharma HM, Nahman NS Jr (1989) Acute renal failure with glomerular thrombosis in a patient with chronic scleroderma. Am J Kidney Dis 14:524\u2013526","journal-title":"Am J Kidney Dis"},{"key":"357_CR88","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1159\/000186616","volume":"59","author":"A Meyrier","year":"1991","unstructured":"Meyrier A, Becquemont L, Weill B, Callard P, Rainfray M (1991) Hemolytic-uremic syndrome with anticardiolipin antibodies revealing paraneoplastic systemic scleroderma. Nephron 59:493\u2013496","journal-title":"Nephron"},{"key":"357_CR89","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3109\/08860229809045170","volume":"20","author":"YS Haviv","year":"1998","unstructured":"Haviv YS, Safadi R (1998) Normotensive scleroderma renal crisis: case report and review of the literature. Ren Fail 20:733\u2013736","journal-title":"Ren Fail"},{"key":"357_CR90","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00296-008-0826-y","volume":"29","author":"WS Chen","year":"2009","unstructured":"Chen WS, Young AH, Wang HP, Huang DF (2009) Hemolytic uremic syndrome with ischemic glomerulonephropathy and obliterative vasculopathy in a systemic sclerosis patient treated with cyclosporine-A. Rheumatol Int 29:821\u2013824","journal-title":"Rheumatol Int"},{"key":"357_CR91","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","volume":"8","author":"CP Thomas","year":"2015","unstructured":"Thomas CP, Nester CM, Phan AC, Sharma M, Steele AL, Lenert PS (2015) Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome. Clin Kidney J 8:698\u2013701","journal-title":"Clin Kidney J"},{"key":"357_CR92","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF01074143","volume":"21","author":"GE Craner","year":"1976","unstructured":"Craner GE, Burdick GE (1976) Acute colitis resembling ulcerative colitis in the hemolytic-uremic syndrome. Am J Dig Dis 21:74\u201376","journal-title":"Am J Dig Dis"},{"key":"357_CR93","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199005103221903","volume":"322","author":"O Ahrenstedt","year":"1990","unstructured":"Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hallgren R (1990) Enhanced local production of complement components in the small intestines of patients with Crohn\u2019s disease. N Engl J Med 322:1345\u20131349","journal-title":"N Engl J Med"},{"key":"357_CR94","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2249.2010.04093.x","volume":"160","author":"T Sugihara","year":"2010","unstructured":"Sugihara T, Kobori A, Imaeda H et al (2010) The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease. Clin Exp Immunol 160:386\u2013393","journal-title":"Clin Exp Immunol"},{"key":"357_CR95","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.33.7.902","volume":"33","author":"TS Halstensen","year":"1992","unstructured":"Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P (1992) Surface epithelium related activation of complement differs in Crohn\u2019s disease and ulcerative colitis. Gut 33:902\u2013908","journal-title":"Gut"},{"key":"357_CR96","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3109\/0886022X.2014.917574","volume":"36","author":"H Green","year":"2014","unstructured":"Green H, Harari E, Davidovits M et al (2014) Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail 36:1119\u20131121","journal-title":"Ren Fail"},{"key":"357_CR97","doi-asserted-by":"crossref","first-page":"105","DOI":"10.9734\/IJMPCR\/2015\/18771","volume":"4","author":"TN Webb","year":"2015","unstructured":"Webb TN, Griffiths H, Miyashita Y et al (2015) Atypical hemolytic uremic syndrome and chronic ulcerative colitis treated with eculizumab. Int J Med Pharm Case Reports 4:105\u2013112","journal-title":"Int J Med Pharm Case Reports"},{"key":"357_CR98","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN (2015) Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 125:616\u2013618","journal-title":"Blood"},{"key":"357_CR99","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","volume":"90","author":"JA Reese","year":"2015","unstructured":"Reese JA, Bougie DW, Curtis BR et al (2015) Drug-induced thrombotic microangiopathy: experience of the Oklahoma registry and the BloodCenter of Wisconsin. Am J Hematol 90:406\u2013410","journal-title":"Am J Hematol"},{"key":"357_CR100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","volume":"66","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Perazella MA (2015) Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66:857\u2013868","journal-title":"Am J Kidney Dis"},{"key":"357_CR101","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1158\/1078-0432.CCR-11-0804","volume":"17","author":"JA Blake-Haskins","year":"2011","unstructured":"Blake-Haskins JA, Lechleider RJ, Kreitman RJ (2011) Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res 17:5858\u20135866","journal-title":"Clin Cancer Res"},{"key":"357_CR102","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00002018-200124070-00002","volume":"24","author":"R Pisoni","year":"2001","unstructured":"Pisoni R, Ruggenenti P, Remuzzi G (2001) Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf 24:491\u2013501","journal-title":"Drug Saf"},{"key":"357_CR103","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","volume":"6","author":"S Faguer","year":"2013","unstructured":"Faguer S, Huart A, Fremeaux-Bacchi V, Ribes D, Chaveau D (2013) Eculizumab and drug-induced haemolytic-uraemic syndrome. Clin Kidney J 6:484\u2013485","journal-title":"Clin Kidney J"},{"key":"357_CR104","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5414\/CN108163","volume":"83","author":"K Safa","year":"2015","unstructured":"Safa K, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R (2015) Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report. Clin Nephrol 83:125\u2013129","journal-title":"Clin Nephrol"},{"key":"357_CR105","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","volume":"360","author":"J Nurnberger","year":"2009","unstructured":"Nurnberger J, Philipp T, Witzke O et al (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542\u2013544","journal-title":"N Engl J Med"},{"key":"357_CR106","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjh.12686","volume":"164","author":"M Starck","year":"2014","unstructured":"Starck M, Wendtner CM (2014) Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol 164:894\u2013896","journal-title":"Br J Haematol"},{"key":"357_CR107","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MNH.0b013e328365b3fe","volume":"22","author":"M Noris","year":"2013","unstructured":"Noris M, Remuzzi G (2013) Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 22:704\u2013712","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"357_CR108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G et al (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339","journal-title":"Pediatr Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-016-0357-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-016-0357-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-016-0357-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:57Z","timestamp":1777564617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/30\/3\/347\/8371256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["357"],"URL":"https:\/\/doi.org\/10.1007\/s40620-016-0357-7","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]}}}